Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Spectrum Pharmaceuticals Inc is a biotechnology business based in the US. Spectrum Pharmaceuticals shares (SPPI) are listed on the NASDAQ and all prices are listed in US Dollars. Spectrum Pharmaceuticals employs 175 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.80|
|52-week range||$1.92 - $5.24|
|50-day moving average||$2.15|
|200-day moving average||$2.97|
|Wall St. target price||$6.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.21|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||-9.55%|
|1 month (2021-09-28)||-22.41%|
|3 months (2021-07-28)||-45.45%|
|6 months (2021-04-28)||-41.18%|
|1 year (2020-10-27)||-47.21%|
|2 years (2019-10-25)||-77.07%|
|3 years (2018-10-26)||12.11|
|5 years (2016-10-27)||3.77|
|Revenue TTM||$109.3 million|
|Gross profit TTM||$0|
|Return on assets TTM||-51.46%|
|Return on equity TTM||-153.89%|
|Market capitalisation||$326.5 million|
TTM: trailing 12 months
There are currently 18.2 million Spectrum Pharmaceuticals shares held short by investors – that's known as Spectrum Pharmaceuticals's "short interest". This figure is 15% up from 15.8 million last month.
There are a few different ways that this level of interest in shorting Spectrum Pharmaceuticals shares can be evaluated.
Spectrum Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Spectrum Pharmaceuticals shares currently shorted divided by the average quantity of Spectrum Pharmaceuticals shares traded daily (recently around 2.7 million). Spectrum Pharmaceuticals's SIR currently stands at 6.78. In other words for every 100,000 Spectrum Pharmaceuticals shares traded daily on the market, roughly 6780 shares are currently held short.
However Spectrum Pharmaceuticals's short interest can also be evaluated against the total number of Spectrum Pharmaceuticals shares, or, against the total number of tradable Spectrum Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Spectrum Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Spectrum Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1361% of the tradable shares (for every 100,000 tradable Spectrum Pharmaceuticals shares, roughly 136 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Spectrum Pharmaceuticals.
Find out more about how you can short Spectrum Pharmaceuticals stock.
We're not expecting Spectrum Pharmaceuticals to pay a dividend over the next 12 months.
Spectrum Pharmaceuticals's shares were split on a 1:25 basis on 5 September 2002. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Spectrum Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Spectrum Pharmaceuticals shares which in turn could have impacted Spectrum Pharmaceuticals's share price.
Over the last 12 months, Spectrum Pharmaceuticals's shares have ranged in value from as little as $1.92 up to $5.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Spectrum Pharmaceuticals's is 2.0921. This would suggest that Spectrum Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Spectrum Pharmaceuticals, Inc. , a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd. ; a patent and technology license agreement with The University of Texas M. D.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.